Introduction {#Sec1}
============

Approximately 1.25 million Americans have chronic hepatitis B infection (CHB). Patients with CHB are at significant lifetime risk for developing cirrhosis, liver failure, and hepatocellular carcinoma (HCC) \[[@CR1]\]. CHB is especially prevalent among Asians and these patients have a threefold or greater increase in the rate of HCC as compared to non-Hispanic Whites \[[@CR2]--[@CR4]\]. The prevalence of CHB varies nationwide due largely to immigration patterns from high-risk areas. In the San Francisco Bay Area, where one-fourth of the population is from the highly endemic regions of Asia and the Pacific Islands, the reported prevalence of CHB is as high as 9% among these individuals \[[@CR5]\]. Moreover, in 2006 the San Francisco Department of Public Health reported that 84% of probable cases of HBV infection occurred in the Asian American and Pacific Islander (AAPI) populations \[[@CR6]\]. Thirty percent of the patients in the San Francisco's safety net healthcare system are AAPIs \[[@CR7]\]. Most of the patients in this system are uninsured or underinsured and have significant health care disparities \[[@CR8], [@CR9]\]. In order to reduce the burden of HCC among AAPIs, it is important that these patients are screened for HBV and, depending on their status, receive HBV vaccination or HCC screening as appropriate, especially within the safety net healthcare systems \[[@CR10]\].

Hepatocellular carcinoma screening can detect early stage disease and may improve survival in the presence of curative treatment options \[[@CR11]\]. Practice guidelines published by the American Association for the Study of Liver Diseases (AASLD) recommend HCC screening in high-risk populations, including Asians with CHB \[[@CR12]\]. The recommended screening test is liver ultrasound every 6--12 months. Studies have shown that the majority of providers recommend HCC screening to their patients \[[@CR13], [@CR14]\], however, there is no information on the screening modalities typically employed by providers within the context of CHB infection. In addition, although there is limited data on provider knowledge, attitudes, and perceived barriers to HCC surveillance among HBV-infected Asian Americans \[[@CR14], [@CR15]\], there are no studies evaluating these factors within the resource-limited safety net healthcare systems. This information is crucial in identifying interventions to reduce disparities in health and health care in this at-risk population.

In this study we aimed to characterize provider-reported screening practices for HBV and HCC along with provider knowledge, attitudes, and perceived barriers to HCC screening among Asian Americans by surveying a large network of providers within San Francisco's safety net healthcare system.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a cross-sectional survey of primary care and specialty providers who provide health care in clinics affiliated with the San Francisco's safety net healthcare system, which annually provides care for over 150,000 patients, including most of the county's uninsured residents \[[@CR7]\]. This system is composed of the San Francisco Community Clinic Consortium, which has ten nonprofit primary care community health centers, and the San Francisco Department of Public Health's Community Health Network, which includes 11 community-based primary care clinics and one acute care hospital (San Francisco General Hospital) with on-site primary and specialty care clinics \[[@CR7]\]. The survey was sent to the 150 providers from these primary care clinics and three specialty (gastroenterology, hepatology, HIV/infectious diseases) clinics by mail or electronic mail between December 1, 2007, and March 31, 2008. A second mailing to non-respondents was conducted after 4 weeks. Respondents chose a \$10 gift certificate or a chance for a \$100 gift card as incentives. The study was approved by the Committee on Human Research of the University of California, San Francisco, and the SFGH Data Governance Committee.

Survey Design {#Sec4}
-------------

The survey instrument was developed by the study investigators with input from hepatology expert opinion and previously published surveys. Content domains included provider and practice characteristics, HBV screening and CHB management practices, HCC surveillance practices and modalities employed, provider knowledge of HBV and HCC, and attitudes toward (and perceived barriers to) HCC surveillance. The survey was pilot-tested with 20 physicians and revised.

Data Definitions and Statistics {#Sec5}
-------------------------------

Provider and practice characteristics were summarized using mean ± SD, median (range), and frequencies. In order to assess overall provider knowledge, favorable attitudes, and barriers to performing HCC surveillance, scores were formed from the responses to questions assessing these factors. The knowledge score was computed as the number of correct responses to the four questions assessing knowledge (minimum 0, maximum 4). The attitude score was determined by summing the numerical codes assigned to responses to eight questions assessing provider attitudes as follows: 1 to an "agree" response, 0.5 to "unsure" response, and "0" to a "disagree" response. The barrier score was computed as the number of barriers from a list of 11 categories including an "other" category identified by the providers. Screening for HCC was defined as performing ultrasound every 6--12 months. To evaluate provider and practice factors associated with HBV and HCC screening, univariate analysis was performed using Student\'s *t* test for continuous variables and Chi-square (Fishers exact test when appropriate) tests for categorical variables. Multivariable logistic regression modeling evaluating factors associated with HBV and HCC screening included independent predictors from an a priori compiled list as well as those with a *p* value ≤0.2 as determined by the univariate analysis. Statistical significance was assessed at the *p* value of \<0.05 level (two-sided) in all models. All analyses were performed using STATA version 8.0 (STATA Corporation, College Station, TX).

Results {#Sec6}
=======

Provider and Practice Characteristics {#Sec7}
-------------------------------------

Out of 150 providers, 109 returned the survey, a response rate of 72%. Provider characteristics are shown in Table [1](#Tab1){ref-type="table"}. Most (87%) were primary care providers, 9% were hepatologists and gastroenterologists, and 80% held an MD degree. The majority were above age 40 and 65% were female. Thirty-one percent were Asian and half had been in practice for more than 10 years. Twenty-four percent of all providers and 77% of the Asian providers spoke an Asian language. About half (48%) reported that Asian patients comprised over 25% of their patient population and 53% reported that among their Asian patients, more than 50% had limited English proficiency. The majority of patients in the practices surveyed were either uninsured or had public insurance.Table 1Provider and practice characteristics in the San Francisco safety net healthcare systemAge (%) (years) 20--296 30--3929 40--4928 50--5928 ≥609Female (%)65Race/ethnicity (%) Caucasian61 African-American1 Asian/Pacific Islander31 Latino6 Other1Born in United States (%)85Speak Asian language (%)24Post-graduate degree (%) MD80 Nurse practitioner17 Other3Specialty (%) Internal medicine46 Family practice41 Gastroenterology/hepatology9 Infectious disease2 Other2Years in practice (%) 0--1050 11--2043 \>207Median number of patients seen per week (range)30 (5--100)More than 25% Asian patients48More than 50% of Asian patients with limited English proficiency53Median proportion of patients in practice with Private insurance5 Public insurance50 Uninsured40(*n* = 109)

HBV Screening, Vaccination, and HCC Screening {#Sec8}
---------------------------------------------

Provider management practices relating to HBV screening, HBV vaccination, and HCC surveillance among Asian patients are summarized in Table [2](#Tab2){ref-type="table"}. Only 76% of the providers reported that \>50% of their Asians patients had been screened for HBV. Only 43% of the providers reported that \>50% of their eligible patients had received HBV vaccination. A multitude of HBV screening practices were reported: 48% ordered HBsAg only; 16% used HBsAg and anti-HBs in combination; 24% used HBsAg in combination with anti-HBs and total anti-HBc; 9% used HBsAg and total anti-HBc; 2% used anti-HBc; and 1% used HBV viral load.Table 2HBV screening, vaccination, and management among San Francisco safety net providersScreening and managementProportion (%)Proportion of Asian patients that have been screened for HBV ≤25%10 26--50%11 51--74%26 ≥75%50Not sure3Proportion of eligible patients that have been vaccinated against HBV ≤25%25 26--50%21 51--74%26 ≥75%17 Not sure11Proportion of Asian patients with chronic HBV that have been vaccinated against HAV ≤25%17 26--50%10 51--74%11 ≥75%50 Not sure12Proportion of Asian patients with chronic HBV that have been screened for HCC ≤25%4 26--50%10 51--74%13 ≥75%66 Not sure7Offers therapy for HBV35*HAV* hepatitis A virus, *HBV* hepatitis B virus, *HCC* hepatocellular carcinoma

There was also considerable variation in defining high-risk populations for HCC screening---60% would screen all patients with CHB, 11% would screen Asian patients with CHB, 6% would screen only in patients with HBV-induced cirrhosis, and 23% would screen a combination of these groups. Only 79% reported that they had screened for HCC in \>50% of their Asian patients with CHB. Although 27% of providers were unfamiliar with the AASLD guidelines for HCC screening in HBV patients, 94% reported that they perform HCC screening among CHB patients.

HCC Screening Modalities {#Sec9}
------------------------

Providers were asked to report which of several laboratory or imaging studies they used for HCC screening, either alone or in combination. Overall, 91% used alpha fetoprotein (AFP); 79% used ultrasound (US); 71% used AST and/or ALT; 46% used other imaging modalities; and 30% used HBV viral load (Fig. [1](#Fig1){ref-type="fig"}). The most commonly used modalities reported were AFP (90%) and US (78%) at a frequency of every 6--12 month. Among the 88% who indicated that they used a combination of AFP and an imaging study for HCC surveillance every 6--12 months, 63% used US, 8% used computed tomography (CT), and 29% used more than one type of imaging. Only 3% of respondents used AFP alone and 5% used imaging alone for HCC surveillance.Fig. 1Hepatocellular carcinoma screening modalities utilized by providers. The providers were asked whether they used any of the following laboratory and abdominal imaging modalities as a screening tool for hepatocellular carcinoma. The figure summarizes the responses of providers with regards to the type of test and the frequency of the test used in their practice for hepatocellular carcinoma surveillance. *AFP* alpha fetoprotein, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *US* ultrasound, *CT* computed tomography, *MRI* magnetic resonance imaging, *HBV DNA* hepatitis B viral load

Provider Knowledge, Attitudes, and Barriers to HCC Screening {#Sec10}
------------------------------------------------------------

Knowledge, attitudes, and barriers to HCC screening are summarized in Table [3](#Tab3){ref-type="table"}. Nearly all providers knew that CHB was the most common cause of HCC among Asians and that Asians had a higher incidence of HCC compared to Whites. Three-quarters indicated that treating CHB can prevent HCC. About 70% believed that HCC screening in patients with CHB reduces HCC mortality and over half thought that screening is cost-effective and not screening poses a malpractice risk. The most common factors that influence a provider's decision to order any cancer-screening test were recommendations by a national organization (93%) and good evidence that screening decreases mortality (99%). The most common perceived barriers influencing a provider's decision to perform HCC screening among patients with CHB were lack of imaging resources (59%), unclear HCC screening guidelines (35%), difficulty accessing specialty care (35%), and patient financial barriers (31%).Table 3Provider knowledge, attitudes, and barriers towards hepatocellular carcinoma (HCC) surveillanceKnowledge (mean score 3.3 ± 0.8)Correct answers (%)Asians have same incidence of liver cancer as Whites94Most common cause of liver cancer in Asians is HBV95Treating HBV can prevent liver cancer77HCC screening in HBV reduces liver cancer mortality70Attitude (mean score = 5.8 ± 1.6)Percent agreeNot screening for HCC is a malpractice risk59Screening for HCC is cost-effective57Will perform cancer screening when it is recommended by a national organization93Will perform cancer screening when my patients ask for it69Will perform cancer screening when it is used as a quality measure at my institution or by insurance companies72Will perform cancer screening when it is covered by health insurance62Will perform cancer screening when I see an increasing frequency of cancer in my practice56Will perform cancer screening when there is good evidence that screening leads to decreased mortality99Provider perceived barriers (mean score = 2.3 ± 1.7)Percent agreeLack of clarity of liver cancer-screening guidelines35Discomfort with discussing liver cancer screening1Lack of effectiveness of cancer screening12Lack of US/CT/MRI screening resources59Lack of effective therapy for liver cancer15Difficulty accessing specialty (GI/hepatology) care35Lack of blood testing resources4Language access barriers with patient18Patient financial barriers31Uncertain/unaware of liver cancer screening guidelines27*HBV* hepatitis B virus, *HCC* hepatocellular carcinoma

Factors Associated with Performing the Recommended HBV and HCC Screening {#Sec11}
------------------------------------------------------------------------

Factors associated with the higher likelihood of reporting HBV screening among \>50% of Asian patients in univariate analysis included having performed HBV vaccination in \>50% of eligible patients (94 vs. 60%, *p* \< 0.0001), HCC screening in \>50% of CHB patients in practice (86 vs. 43%, *p* \< 0.0001), familiarity with AASLD guidelines (84 vs. 52%, *p* = 0.001), and provider age less than 40 years (88 vs. 68%, *p* = 0.02). The rate of HBV screening (in more than 50% of their Asian patients) was not significantly different among those providers who spoke an Asian language versus those who did not speak an Asian language (88 vs. 70%, *p* = 0.07). In addition, although a higher rate of HBV screening was reported by providers at safety net health centers with a high proportion of Asian providers who speak an Asian language, this did not reach statistical significance (90 vs. 72%, *p* = 0.07). On multivariable analysis when controlling for provider age, gender, race, years in practice, and specialty, familiarity with AASLD guidelines (OR 6.4, 95% CI 1.3--30.1, *p* = 0.02) and having vaccinated against HBV in \>50% of eligible patients (OR 2.2, 95% CI 1.1--4.5, *p* = 0.03) were significantly associated with a higher likelihood of reporting HBV screening among \>50% of Asian patients.

For HCC screening, in univariate analysis, performing US every 6--12 months was associated with having \>25% or more Asian patients \[53% (45/85) vs. 25% (6/24), *p* = 0.02\] and higher knowledge score (3.0 ± 0.9 vs. 3.4 ± 0.8, *p* = 0.01). There was no statistically significant difference in performing US every 6--12 months among providers who spoke an Asian language compared to those who did not speak an Asian language (88 vs. 75%, *p* = 0.2) and among providers from centers with a high proportion of Asian providers who spoke an Asian language compared to those who did not practice at these centers (90 vs. 75%, *p* = 0.1). In multivariate analysis after controlling for provider age, gender, race, years in practice, and medical specialty the same two variables, having \>25% of Asian patients in the practice (OR = 4.5, 95% CI 1.3--15.3, *p* = 0.02) and having a higher knowledge score (OR = 1.9, 95% CI 1.01--3.6, *p* = 0.045), remained significantly associated with performing ultrasound every 6--12 months (Table [4](#Tab4){ref-type="table"}).Table 4Multivariate regression analysis of factors associated with hepatocellular carcinoma screening with abdominal ultrasound every 6--12 monthsVariableOdds ratio95% CI*p* valueAge (per decade)0.70.3--1.70.5Female gender0.50.1--1.60.2Provider race (Asian vs. non-Asian)0.40.1--1.60.2More than 10 years in practice1.30.3--6.70.3Specialty (primary care vs. GI/hepatology)0.20.03--1.10.06Familiarity with AASLD practice guidelines on HCC screening1.90.5--6.51.0More than 25% Asian patients in practice4.51.3--15.30.02Provider knowledge score1.91.01--3.60.045Provider attitude score1.10.8--1.60.5Provider barrier score1.010.7--1.40.06

Discussion {#Sec12}
==========

This is the first study to evaluate provider-reported HBV and HCC screening practices as well as knowledge, attitudes, and barriers towards HCC screening among Asian Americans in a safety net healthcare system. Respondents reported suboptimal rates of screening for and vaccination against HBV among Asians and screening for HCC. Having a higher rate of HBV vaccination in practice and familiarity with AASLD guidelines was associated with higher rates of HBV screening whereas having a large proportion of at-risk Asian patients and greater provider knowledge of HCC's relationship to HBV were associated with HCC screening.

At the time of this survey, the Center for Disease Control and Prevention (CDC) recommended HBV screening in Asian and Pacific Islanders and vaccination of all eligible at-risk patients. The current HBV screening recommendations also include US born persons not vaccinated as infants whose parents were born in regions with high HBV endemicity \[[@CR16]\]. The recent Institute of Medicine Hepatitis and Liver Cancer Report also emphasizes the importance of HBV screening and vaccination \[[@CR17]\]. Studies to date have shown that HBV screening and vaccination among Asian Americans are suboptimal at rates of 35--65% \[[@CR15], [@CR18]--[@CR20]\]. Similarly, only half of the providers in this study estimated that 75% or more of their Asian patients were screened for HBV infection and less than half of the providers had vaccinated the majority of their eligible Asian patients. Both patient and provider factors impact HBV screening and vaccination and provider knowledge represents an especially important factor \[[@CR14], [@CR17]\]. Previous studies have shown that Asians are more likely to get screened and vaccinated against HBV if recommended by a medical provider \[[@CR18]\]. In contrast, the lack of patient English-language fluency and low socioeconomic status are associated with lower rates of HBV screening and vaccination \[[@CR21]\]. The majority of the patients in the practices surveyed in this study had low socioeconomic status and were uninsured or had public medical insurance and approximately half of the providers indicated that more than 50% of their Asian patients spoke little or no English. Our results, however, did not show an association between provider race (Asian vs non-Asian) or ability to speak an Asian Language and increased HBV or HCC screening. This finding may be due to the sample size, which may not be adequately powered to detect a difference. However, while one might expect that providers who are Asian or who speak an Asian language may have a heightened awareness of hepatitis B and better communicate the need for HBV and HCC screening to their patients, the data in the literature are conflicting. While there are reports of providers with Asian language abilities performing more HBV screening among Chinese-speaking patients \[[@CR15]\], others have not found an association between provider race (Asian vs non-Asian) and Asian language and HCC screening among at-risk populations similar to our study \[[@CR14]\]. In fact, in our study, only provider familiarity with HBV screening and vaccination recommendations rather than patient related factors were significantly associated with higher rates of HBV screening. Thus, provider-targeted interventions should address ways to enhance their knowledge of current recommendations.

We have identified some deficit in knowledge with respect to HBV screening modalities utilized among providers. The combination of HBsAg and Anti-HBs has been recommended for HBV screening \[[@CR22]\]. Nearly all providers in our study correctly included HBsAg, a test that detects active disease, as an HBV screening test, but 48% did not test for anti-HBs, which is necessary to assess eligibility for vaccination. This may reflect the lack of knowledge about the need for vaccination in this high-risk population. Moreover, this may lead to unnecessary vaccination of those already immune, thereby driving up costs in a resource-poor healthcare system.

The most common cause of HCC among Asian Americans is CHB, and strategies for primary and secondary HCC prevention are critical in reducing cancer disparity in this group. In this study, we investigated provider knowledge of HCC and attitudes towards HCC screening. The majority of providers who responded were well informed about the risk of HCC among Asian Americans with CHB and recognized that primary prevention with HBV treatment can decrease the incidence of HCC \[[@CR22]--[@CR24]\]. Secondary prevention with HCC surveillance is recommended by national organizations. However, improvement in rates of HCC surveillance performed by this group of safety net healthcare providers is required in order to adhere to these recommendations.

There are limitations to the available data on survival benefit of HCC screening. Nevertheless, one randomized controlled trial and other prospective observational studies have shown that HCC screening may result in reduced mortality, specifically when curative therapy is available \[[@CR11], [@CR25], [@CR26]\]. Similar to other survey studies, nearly all of the providers in this study agreed that cancer surveillance should be performed when there is strong evidence that mortality is reduced \[[@CR14]\] and that they had recommended HCC surveillance to their patients. However, about 30% of providers were either unsure or did not believe that HCC screening in CHB patients improved survival and a third were unfamiliar with the AASLD guidelines endorsing surveillance.

In this study, predictors of adherence to the AASLD guidelines using ultrasound every 6--12 months for HCC surveillance in at-risk populations were assessed \[[@CR12]\]. The most common screening modality, utilized by about two-thirds of the respondents, was a combination of ultrasound and AFP at the frequency of 6--12 months. However, providers also used liver enzymes and HBV viral load, as well as radiologic modalities other than ultrasound that are not recommended as HCC screening tests. Factors associated with performing the recommended screening test in multivariable analysis included having a high proportion of at-risk Asian Americans in practice and greater provider knowledge of HBV-associated HCC. In a national survey of 459 primary providers and specialists identified through the American Medical Association Masterfile, Nguyen et al. \[[@CR14]\] showed that the physicians who had a higher knowledge of HBV management were more likely to screen for HCC and that the concern for malpractice risk and the use of HCC screening as a quality measure increased the odds of screening. In another survey of 217 family physicians, HCC screening in CHB patients was related to years in practice, female physicians, and group practice \[[@CR27]\]. In contrast, we did not find an independent association between HCC surveillance and physician characteristics or the overall provider attitude score, which included risk of malpractice and quality indicators.

The main limitation of this study is self-reported practice patterns, whereas the main strength is the high response rate. However, in general self-report tends to overestimate screening rates \[[@CR28]\] and thus this limitation is unlikely to threaten our finding of suboptimal reported rates of screening for HBV and HCC by the study population. Generalizations to other practice settings is also limited, since surveyed practices had a high proportion of Asians, which may result in a heightened awareness of CHB and HCC disease that can underestimate the deficiencies in provider knowledge and rates of HBV and HCC screening in other practice settings with lower at-risk patient populations. Nevertheless, our findings uncovered suboptimal HBV screening and vaccination rates even among providers with high exposure to at-risk populations. As several factors including patient adherence likely play a role in rates of HBV screening, vaccination, and HCC surveillance, review of patient health records are required to confirm results obtained from provider reports.

In summary, our findings suggest that HBV screening and vaccination of eligible patients and education about the recommended tests for HBV screening and HCC surveillance are potential areas requiring improvement among providers. However, safety net providers are knowledgeable about cancer disparity among Asian Americans and are motivated to perform HCC surveillance even in the presence of limited resources. Our research supports the findings of the recent Institute of Medicine Report on Hepatitis and Liver Cancer \[[@CR17]\] that ongoing education of patients and providers as well as investment in infrastructure to improve access to and quality of HBV care are key intervention strategies to reduce the HBV disease burden and the related cancer disparity among Asian Americans.
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